Merck Price to Sales Ratio 2012-2026 | MRK
Historical PS ratio values for Merck (MRK) over the last 10 years. The current P/S ratio for Merck as of September 08, 2026 is .
| Merck P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2026-09-08 | 148.46 | 5.55 | |
| 2026-06-30 | 128.50 | $26.77 | 4.80 |
| 2026-03-31 | 119.43 | $26.34 | 4.53 |
| 2025-12-31 | 103.74 | $25.88 | 4.01 |
| 2025-09-30 | 82.02 | $25.49 | 3.22 |
| 2025-06-30 | 76.60 | $25.13 | 3.05 |
| 2025-03-31 | 86.00 | $25.17 | 3.42 |
| 2024-12-31 | 94.49 | $25.24 | 3.74 |
| 2024-09-30 | 107.01 | $24.83 | 4.31 |
| 2024-06-30 | 115.88 | $24.55 | 4.72 |
| 2024-03-31 | 122.78 | $24.14 | 5.09 |
| 2023-12-31 | 100.80 | $23.61 | 4.27 |
| 2023-09-30 | 94.50 | $23.31 | 4.05 |
| 2023-06-30 | 105.21 | $22.93 | 4.59 |
| 2023-03-31 | 96.36 | $22.75 | 4.24 |
| 2022-12-31 | 99.79 | $23.34 | 4.28 |
| 2022-09-30 | 76.95 | $23.23 | 3.31 |
| 2022-06-30 | 80.81 | $22.53 | 3.59 |
| 2022-03-31 | 72.14 | $21.27 | 3.39 |
| 2021-12-31 | 66.79 | $19.19 | 3.48 |
| 2021-09-30 | 64.84 | $17.47 | 3.71 |
| 2021-06-30 | 66.54 | $16.59 | 4.01 |
| 2021-03-31 | 62.40 | $15.79 | 3.95 |
| 2020-12-31 | 65.63 | $16.34 | 4.02 |
| 2020-09-30 | 66.04 | $14.34 | 4.61 |
| 2020-06-30 | 61.12 | $14.85 | 4.12 |
| 2020-03-31 | 60.33 | $15.71 | 3.84 |
| 2019-12-31 | 70.73 | $15.13 | 4.68 |
| 2019-09-30 | 65.02 | $17.62 | 3.69 |
| 2019-06-30 | 64.34 | $16.84 | 3.82 |
| 2019-03-31 | 63.39 | $16.17 | 3.92 |
| 2018-12-31 | 57.85 | $15.72 | 3.68 |
| 2018-09-30 | 53.33 | $15.41 | 3.46 |
| 2018-06-30 | 45.32 | $15.17 | 2.99 |
| 2018-03-31 | 40.36 | $14.89 | 2.71 |
| 2017-12-31 | 41.33 | $14.60 | 2.83 |
| 2017-09-30 | 46.64 | $14.43 | 3.23 |
| 2017-06-30 | 46.35 | $14.43 | 3.21 |
| 2017-03-31 | 45.61 | $14.35 | 3.18 |
| 2016-12-31 | 41.96 | $14.27 | 2.94 |
| 2016-09-30 | 44.14 | $14.24 | 3.10 |
| 2016-06-30 | 40.45 | $14.01 | 2.89 |
| 2016-03-31 | 36.85 | $13.91 | 2.65 |
| 2015-12-31 | 36.47 | $13.87 | 2.63 |
| 2015-09-30 | 33.81 | $13.85 | 2.44 |
| 2015-06-30 | 38.64 | $13.93 | 2.77 |
| 2015-03-31 | 38.71 | $14.20 | 2.73 |
| 2014-12-31 | 37.94 | $14.37 | 2.64 |
| 2014-09-30 | 39.31 | $14.57 | 2.70 |
| 2014-06-30 | 38.08 | $14.67 | 2.60 |
| 2014-03-31 | 37.09 | $14.62 | 2.54 |
| 2013-12-31 | 32.45 | $14.66 | 2.21 |
| 2013-09-30 | 30.59 | $14.70 | 2.08 |
| 2013-06-30 | 29.58 | $14.70 | 2.01 |
| 2013-03-31 | 27.89 | $15.05 | 1.85 |
| 2012-12-31 | 25.58 | $15.37 | 1.66 |
| 2012-09-30 | 27.92 | $15.53 | 1.80 |
| 2012-06-30 | 25.60 | $15.69 | 1.63 |
| 2012-03-31 | 23.29 | $15.59 | 1.49 |
| 2011-12-31 | 22.61 | $15.50 | 1.46 |
| 2011-09-30 | 19.38 | $15.40 | 1.26 |
| 2011-06-30 | 20.67 | $15.10 | 1.37 |
| 2011-03-31 | 19.13 | $14.82 | 1.29 |
| 2010-12-31 | 20.64 | $14.73 | 1.40 |
| 2010-09-30 | 20.86 | $15.29 | 1.36 |
| 2010-06-30 | 19.61 | $14.57 | 1.35 |
| 2010-03-31 | 20.72 | $13.74 | 1.51 |
| 2009-12-31 | 20.06 | $12.65 | 1.59 |
| 2009-09-30 | 17.19 | $11.03 | 1.56 |
| 2009-06-30 | 15.01 | $10.95 | 1.37 |
| 2009-03-31 | 14.16 | $10.97 | 1.29 |
| 2008-12-31 | 15.83 | $11.09 | 1.43 |
| 2008-09-30 | 16.20 | $11.13 | 1.46 |
| 2008-06-30 | 19.14 | $11.11 | 1.72 |
| 2008-03-31 | 19.08 | $11.09 | 1.72 |
| 2007-12-31 | 28.96 | $11.06 | 2.62 |
| 2007-09-30 | 25.59 | $10.97 | 2.33 |
| 2007-06-30 | 24.47 | $10.68 | 2.29 |
| 2007-03-31 | 21.54 | $10.52 | 2.05 |
| 2006-12-31 | 21.08 | $10.35 | 2.04 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $370.890B | $65.011B |
| Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1081.958B | 36.50 |
| Johnson & Johnson (JNJ) | United States | $663.276B | 25.34 |
| AbbVie (ABBV) | United States | $453.112B | 23.59 |
| Roche Holding AG (RHHBY) | Switzerland | $350.157B | 0.00 |
| Novartis AG (NVS) | Switzerland | $305.285B | 18.43 |
| Novo Nordisk (NVO) | Denmark | $208.069B | 11.59 |
| Pfizer (PFE) | United States | $162.156B | 9.33 |
| Sanofi (SNY) | France | $107.257B | 9.03 |
| Bayer (BAYRY) | Germany | $55.767B | 9.92 |
| Innoviva (INVA) | United States | $1.541B | 5.27 |